Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
How should we use anti-CTLA-4 antibodies?
Marabelle A, Eggermont A. Marabelle A, et al. Eur J Cancer. 2015 Nov;51(17):2686-8. doi: 10.1016/j.ejca.2015.09.002. Eur J Cancer. 2015. PMID: 26613660 No abstract available.
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.
Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Vacchelli E, et al. Among authors: marabelle a. Oncoimmunology. 2015 Feb 3;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan. Oncoimmunology. 2015. PMID: 25949870 Free PMC article. Review.
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.
Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Buqué A, et al. Among authors: marabelle a. Oncoimmunology. 2015 Mar 2;4(4):e1008814. doi: 10.1080/2162402X.2015.1008814. eCollection 2015 Apr. Oncoimmunology. 2015. PMID: 26137403 Free PMC article. Review.
Rationale for anti-OX40 cancer immunotherapy.
Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Aspeslagh S, et al. Among authors: marabelle a. Eur J Cancer. 2016 Jan;52:50-66. doi: 10.1016/j.ejca.2015.08.021. Epub 2015 Nov 30. Eur J Cancer. 2016. PMID: 26645943 Review.
Two cases of immune thrombocytopenia associated with pembrolizumab.
Le Roy A, Kempf E, Ackermann F, Routier E, Robert C, Turpin A, Marabelle A, Mateus C, Michot JM, Lambotte O. Le Roy A, et al. Among authors: marabelle a. Eur J Cancer. 2016 Feb;54:172-174. doi: 10.1016/j.ejca.2015.10.073. Epub 2015 Dec 10. Eur J Cancer. 2016. PMID: 26687374 No abstract available.
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, François H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A. Champiat S, et al. Among authors: marabelle a. Ann Oncol. 2016 Apr;27(4):559-74. doi: 10.1093/annonc/mdv623. Epub 2015 Dec 28. Ann Oncol. 2016. PMID: 26715621 Free article. Review.
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O. Michot JM, et al. Among authors: marabelle a. Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5. Eur J Cancer. 2016. PMID: 26765102 Review.
281 results